Cargando…

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

PURPOSE: Targeting CD79B using antibody–drug conjugates (ADC) is an effective therapeutic strategy in B-cell non-Hodgkin lymphoma (B-NHL). We investigated DCDS0780A, an anti-CD79B ADC with THIOMAB technology (TDC) that consistently conjugates two anti-neoplastic molecules per antibody, in contrast w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrera, Alex F., Patel, Manish R., Burke, John M., Advani, Ranjana, Cheson, Bruce D., Sharman, Jeff P., Penuel, Elicia, Polson, Andrew G., Liao, Chen Di, Li, Chunze, Schuth, Eva, Vaze, Anjali, Samineni, Divya, Elstrom, Rebecca, Cooper, James, Diefenbach, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365381/ https://www.ncbi.nlm.nih.gov/pubmed/34980599 http://dx.doi.org/10.1158/1078-0432.CCR-21-3261

Ejemplares similares

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
por: Harding, James J., et al.
Publicado: (2021)

Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors
por: Sato, Jun, et al.
Publicado: (2022)

Fibroblast Activation Protein-Targeted Radioligand Therapy with (177)Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study
por: Fu, Hao, et al.
Publicado: (2023)

The Effect of Metadherin on NF-κB Activation and Downstream Genes in Ovarian Cancer
por: Rong, Chunhong, et al.
Publicado: (2020)

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
por: Brase, Jan C., et al.
Publicado: (2021)

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
por: Johnson, Melissa, et al.
Publicado: (2022)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
por: Bundred, Nigel, et al.
Publicado: (2022)

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
por: Lim, Emerson A., et al.
Publicado: (2022)

Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment
por: Roschewski, Mark, et al.
Publicado: (2023)

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2018)

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
por: Byrd, John C., et al.
Publicado: (2019)

Indirect Decompression Failure After Lateral Lumbar Interbody Fusion—Reported Failures and Predictive Factors: Systematic Review
por: Kirnaz, Sertac, et al.
Publicado: (2020)

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas
por: Chu, Fuliang, et al.
Publicado: (2023)

In Vitro Generation of Red Blood Cells from Stem Cell and Targeted Therapy
por: Zhou, Ping, et al.
Publicado: (2020)

Claudin-7 Inhibits Proliferation and Metastasis in Salivary Adenoid Cystic Carcinoma Through Wnt/β-Catenin Signaling
por: Ji, Huan, et al.
Publicado: (2020)

Effects of Rapamycin Combined with Cisplatin on Tumor Necrosis Factor TNF-α in MG-63 Cells
por: Han, Tian-Yu, et al.
Publicado: (2020)

The Role of LncRNA H19 in MAPK Signaling Pathway Implicated in the Progression of Bronchopulmonary Dysplasia
por: Mo, Wenhui, et al.
Publicado: (2020)

The Inhibitory Effect of Carboplatin Injection on Human Neuroblastoma SK-N-SH
por: Xu, Jianfeng, et al.
Publicado: (2020)

Infection of Placental Extravillous Cytotrophoblasts with Human Cytomegalovirus Causes a Treg/Th17 Imbalance at the Maternal–Fetal Interface
por: Qiao, Yuan, et al.
Publicado: (2020)

Long Noncoding RNA ZFAS1 Promotes Progression of NSCLC via Regulating of miR-590-3p
por: Zhou, Yumei, et al.
Publicado: (2020)

A Likely Role for a Novel Cell Therapeutic Target of Transforming Growth Factor-β1 on Radiation Pneumonitis in Lung and Nasopharyngeal Cancer Patients
por: Yin, Qin, et al.
Publicado: (2020)

Enhanced UV Resistance Role of Death Domain–Associated Protein in Human MDA-MB-231 Breast Cancer Cells by Regulation of G2 DNA Damage Checkpoint
por: Shan, Zhiyan, et al.
Publicado: (2020)

MicroRNA-497-5p Functions as a Modulator of Apoptosis by Regulating Metadherin in Ovarian Cancer
por: Liu, Chunyan, et al.
Publicado: (2020)

Calcium-dependent Protein Kinases in Malaria Parasite Development and Infection
por: Ghartey-Kwansah, George, et al.
Publicado: (2020)

Protective Effects of Human Milk-Derived Exosomes on Intestinal Stem Cells Damaged by Oxidative Stress
por: Dong, Ping, et al.
Publicado: (2020)

Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
por: Wang, Zhixiong, et al.
Publicado: (2020)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
por: Turner, Nicholas C., et al.
Publicado: (2021)

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2021)

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma
por: Lassman, Andrew B., et al.
Publicado: (2022)

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
por: O'Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
por: Biswas, Tithi, et al.
Publicado: (2022)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

A Randomized Controlled Trial Comparing Two Different Schedules for Cisplatin Treatment in Patients with Locoregionally Advanced Nasopharyngeal Cancer
por: Xia, Wei-Xiong, et al.
Publicado: (2021)

Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
por: Chi, Ping, et al.
Publicado: (2022)

The Endoplasmic Reticulum-Stressed Head and Neck Squamous Cell Carcinoma Cells Induced Exosomal miR-424-5p Inhibits Angiogenesis and Migration of Humanumbilical Vein Endothelial Cells Through LAMC1-Mediated Wnt/β-Catenin Signaling Pathway
por: Wang, Zeyu, et al.
Publicado: (2022)

BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma
por: Mehnert, Janice M., et al.
Publicado: (2022)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hgc0epf0og4cfg9uu7vgdpmstf